N. prodotti: 0
Totale ordine: € 0,00
Official Journal of the , the International Union of Phlebology and the
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899
Online ISSN 1827-1839
Bozkurt A. K. 1, Köksal C. 2, Demirbas M. Y. 1, Erdogan A. 3, Rahman A. 4, Demirkiliç U. 5, Üstünsoy H. 6, Metin G. 7, Yillik L. 8, Önol H. 9, Çinar B. 10, Karaçelik M. 11, Erdinç I. 12, Bolcal C. 5, Sayin A. G. 1, The Turkish Buerger’s Disease Research Group
1 Department of Cardiovascular Surgery, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey
2 Department of Cardiovascular Surgery, Sureyyapasa Thorax and Cardiovascular Diseases Training Hospital, Maltepe-Istanbul, Turkey
3 Department of Cardiothoracic Surgery, Akdeniz University, Faculty of Medicine, Antalya, Turkey
4 Department of Thoracic and Cardiovascular Surgery, Fırat Medical Center, Fırat University, Elazıg˘, Turkey
5 Department of Cardiovascular Surgery, Gulhane Military Medical Academy, Ankara, Turkey
6 Department of Cardiovascular Surgery, School of Medicine, Gaziantep University, Gaziantep, Turkey
7 Department of Cardiovascular Surgery, Çukurova Government Hospital, Adana, Turkey
8 Department of Cardiovascular Surgery, Ataturk Education and Research Hospital, Izmir, Turkey
9 Alsancak Education and Research Hospital, Department of Cardiovascular Surgery, Izmir, Turkey
10 Department of Cardiovascular Surgery, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Center, Istanbul, Turkey
11 Tepecik Training Hospital, Izmir, Turkey
12 Izmir Training Hospital, Izmir, Turkey
Aim. The aim of this study was to compare the effects of iloprost and lumbar sympathectomy (LS) in the treatment of Buerger’s disease.
Methods. Two hundred patients with rest pain and/or ischemic ulcers were randomized to undergo LS or 28-day intravenous treatment of iloprost. The primary endpoint was complete healing without pain or major amputation at 4 and 24 weeks. The secondary endpoints were analgesic requirement, reduction in the ulcer size, 50% reduction of the ulcer, and shift in the modified SVS/ISCVS clinical status grading scale.
Results. The comparison was carried out in 162 patients (iloprost: n=84; LS: n=78). Complete healing rate was 61.9% in the iloprost group, but 41% in the LS group at the 4th week (P=0.012); respective values for the 24th week were 85.3%, 52.3%, P<0.001. Analgesic requirement was lower in the iloprost group at the 4th and 24th weeks (P=0.01, and P=0.098, respectively). The size of the ulcers decreased more in the iloprost group than the LS group (P=0.044 and P=0.035 at 4th and 24th weeks); 50% reduction in the ulcer size in the iloprost group was greater than in the LS group (P=0.001 and P=0.009 at 4th and 24th weeks). SVS/ISCVS grading scale demonstrated a better clinical benefit in patients treated with iloprost (P<0.001 at 4th week, and P<0.001 and at 24th week).
Conclusion. The results of this independent study indicate that using iloprost relieves ischemic symptoms better than LS. In the era of stable prostacyclin analogues, there is no reliable evidence to support the use of LS in Buerger’s disease.